27 Apr 2017 | Livemint.com

BSE
NSE
Last Updated: Mar 31, 03:47 PM
Sun Pharmaceutical Industries Ltd.

BSE

  • 687.70 0.55 (0.08%)
  • Vol: 324976
  • BSE Code: 524715
  • PREV. CLOSE
    687.15
  • OPEN PRICE
    687.00
  • BID PRICE (QTY.)
    0.00(0)
  • OFFER PRICE (QTY.)
    687.70(1170)

NSE

  • 688.15 0.00 (0%)
  • Vol: 2898457
  • NSE Code: SUNPHARMA
  • PREV. CLOSE
    688.15
  • OPEN PRICE
    685.20
  • BID PRICE (QTY.)
    0.00(0)
  • OFFER PRICE (QTY.)
    688.15(1237)

Sun Pharmaceutical Industries Ltd. Board Meetings

From date
To date
Source Date Board Meeting Date Details
31-Jan-201714-Feb-2017 Quarterly Results
25-Oct-201610-Nov-2016 Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 10, 2016, inter alia, to transact the following business: 1. To consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016 (Q2). 2. To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd., with Sun Pharmaceutical Industries Ltd subject to receipt of necessary approvals. & Quarterly Results
02-Aug-201612-Aug-2016 Quarterly Results
16-May-201630-May-2016 Audited Results & Dividend
28-Jan-201612-Feb-2016 Quarterly Results
23-Oct-201507-Nov-2015 Quarterly Results
04-Aug-201511-Aug-2015 With reference to earlier announcement regarding Q1 results on August 11, 2015, Company has now informed BSE that the Board of Directors of the Company at its meeting scheduled to be held on August 11, 201 5 would also transact the following business: 1. Consideration of the revised audited annual accounts of the Company for the year ended March 31, 2015 after giving the effect to the Scheme of Amalgamation of SPGI into SPIL and the proposal for payment of dividend. 2. Consideration of the recommendation of payment of dividend on equity shares for the year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting. & Dividend
28-Jul-201511-Aug-2015 With reference to earlier announcement regarding Q1 results on August 11, 2015, Company has now informed BSE that the Board of Directors of the Company at its meeting scheduled to be held on August 11, 201 5 would also transact the following business: 1. Consideration of the revised audited annual accounts of the Company for the year ended March 31, 2015 after giving the effect to the Scheme of Amalgamation of SPGI into SPIL and the proposal for payment of dividend. 2. Consideration of the recommendation of payment of dividend on equity shares for the year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting. & Dividend
14-May-201529-May-2015 Audited Results
29-Jan-201514-Feb-2015 Quarterly Results
29-Oct-201413-Nov-2014 Quarterly Results